RBC Capital maintains Outperform on Rhythm Pharmaceuticals
RBC Capital maintained its Outperform rating on Rhythm Pharmaceuticals and raised its price target to $159 from $155.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.